Building a responsible development path for surgical robotics¶
Cobodoc is developing collaborative robotic assistance technologies intended to support future clinician-supervised minimally invasive workflows in complex clinical environments.
Cobodoc’s roadmap is structured around responsible development, prototype refinement, validation planning, regulatory strategy, and future workflow integration. Future deployment, training requirements, clinical applications, and commercial availability will depend on development, validation, regulatory clearance, and local clinical practice.
Stage 1 — Early proof-of-concept
Initial feasibility work and technical development activities have supported continued platform development.
Stage 2 — IP protection
Cobodoc controls a surgical-instrument IP portfolio and is preparing additional filings for its next-generation robotic assistance platform.
Stage 3 — Prototype refinement
Ongoing engineering work focuses on prototype refinement, system architecture, software development, and hardware integration.
Stage 4 — Validation planning
Planned activities include preclinical evaluation planning, usability assessment, risk analysis, design documentation, and quality-system preparation.
Stage 5 — Regulatory strategy
Cobodoc is preparing a regulatory strategy to support future clinical-readiness activities, subject to development and validation.
Stage 6 — Partnerships and funding
Cobodoc is seeking strategic partners, accelerators, robotics/deep-tech investors, and non-dilutive funding opportunities, including NIH SBIR/STTR pathways.
Advancing development toward future clinical readiness¶
Cobodoc is advancing engineering development, prototype refinement, preclinical evaluation planning, regulatory strategy, and future clinical-readiness activities. The company’s roadmap is designed to support responsible progression from early proof-of-concept work toward validated, clinician-supervised robotic assistance technologies.
Partner with Cobodoc¶
Cobodoc is seeking qualified investors, accelerators, strategic partners, and non-dilutive funding organizations to support intellectual-property filings, prototype refinement, validation planning, regulatory strategy, quality-system preparation, and U.S. development.
Detailed technical materials, development roadmap, and confidential investor information are available under NDA to qualified partners.